Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.75 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.67 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.63 |
| ▸ | ESR1 | P03372 | 13/20 | 0.63 |
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813263 | 0.89 | APP (0.67) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL5384482 | 0.88 | APP (0.65) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL6172601 | 0.86 | APP (1.00) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL11959810 | 0.86 | APP (0.62) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL31589824 | 0.80 | APP (0.56) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL13477886 | 0.80 | APP (0.56) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL10045302 | 0.80 | APP (0.56) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL32677328 | 0.80 | APP (0.81) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL27159530 | 0.80 | APP (0.81) | APPHSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL12405207 | 0.79 | APP (0.59) | APPHSD17B1HSD17B2ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056339-A1 | Condensed Polycyclic Aromatic Compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056339-A1 | Condensed Polycyclic Aromatic Compound | PAH, AHR, HRH4 | APP 2218/4885HSD17B1 2787/4885HSD17B2 1987/4885 |
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | APP 185/4885HSD17B1 2134/4885HSD17B2 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.